← All trials
NCT02479412
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2015
- Primary completion
- Feb 1, 2016
- Completion date
- Feb 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 110
- Arms / groups
- 9 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- IKF Pneumologie GmbH, Frankfurt, GermanyOverall official - principal investigator
- Insaf GmbH, Wiesbaden, GermanyOverall official - principal investigator
- Clinical Research Hamburg GmbHOverall official - principal investigator
- ParexelOverall official - principal investigator
- University of BonnOverall official - principal investigator
- Comac MedicalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.